Role of central nicotinic and beta-adrenergic receptors in the onset and further development of tail-tremor induced by repeated nicotine administration to rats

Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):571-5. doi: 10.1007/pl00004985.

Abstract

The effects of nicotinic and beta-adrenergic receptor antagonists on tail-tremor induced by repeated nicotine administration were investigated in rats. The daily administration of nicotine (0.5 mg/kg/day, s.c.) for 8 days resulted in an augmentation of tail-tremor. However, repeated administration of dimethyl phenyl piperazinium iodide (1 mg/kg/day, s.c.) for 8 days did not cause tail-tremor. Mecamylamine (0.5 mg/kg, i.p), administered before the nicotine injection on each day, abolished the tail-tremor. After discontinuation of the mecamylamine treatment, nicotine injections caused tail-tremor augmentation. Propranolol (20 mg/kg, i.p.), administered before the nicotine on each day, suppressed the appearance of tail-tremor. After the discontinuation of propranolol treatment, the degree of tail-tremor induced by a single injection of nicotine on day 9 was much greater in the propranolol-treated group than in the saline-treated control group. Neither carteolol (20 mg/kg, i.p.) nor metoprolol (20 mg/kg, i.p.) treatment showed such effects. Intraspinal injection of 6-hydroxydopamine markedly enhanced the tail-tremor induced on the first day of nicotine injection. This effect became more intense on subsequent administration of nicotine. The enhanced tail-tremor following 6-hydroxydopamine treatment was abolished by mecamylamine (0.5 and 1 mg/kg, i.p.), and was suppressed by propranolol (5-20 mg/kg, s.c.) in a dose-dependent manner. These results suggest that central nicotinic receptors are essential for the onset and for the further development of tail-tremor induced by the repeated administration of nicotine, and that beta 2-adrenoceptors are associated with the tremor mechanism. Moreover, spinal noradrenergic mechanisms may be involved in the manifestation of this phenomenon.

MeSH terms

  • Adrenergic Agents / administration & dosage
  • Adrenergic Agents / toxicity
  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Carteolol / administration & dosage
  • Carteolol / pharmacology
  • Dimethylphenylpiperazinium Iodide / administration & dosage
  • Dimethylphenylpiperazinium Iodide / toxicity
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Synergism
  • Injections, Intraperitoneal
  • Injections, Spinal
  • Injections, Subcutaneous
  • Male
  • Mecamylamine / administration & dosage
  • Mecamylamine / pharmacology
  • Metoprolol / administration & dosage
  • Metoprolol / pharmacology
  • Nicotine / administration & dosage
  • Nicotine / toxicity*
  • Nicotinic Agonists / administration & dosage
  • Nicotinic Agonists / toxicity*
  • Nicotinic Antagonists / administration & dosage
  • Nicotinic Antagonists / pharmacology
  • Oxidopamine / administration & dosage
  • Oxidopamine / toxicity
  • Propranolol / administration & dosage
  • Propranolol / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, beta-2 / drug effects
  • Receptors, Adrenergic, beta-2 / metabolism*
  • Receptors, Adrenergic, beta-2 / physiology
  • Receptors, Nicotinic / drug effects
  • Receptors, Nicotinic / metabolism*
  • Receptors, Nicotinic / physiology
  • Tail
  • Tremor / chemically induced*

Substances

  • Adrenergic Agents
  • Adrenergic beta-Antagonists
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • Receptors, Adrenergic, beta-2
  • Receptors, Nicotinic
  • Dimethylphenylpiperazinium Iodide
  • Mecamylamine
  • Nicotine
  • Oxidopamine
  • Carteolol
  • Propranolol
  • Metoprolol